ASCENTAGE PHARMA GROUP INTERNATIONAL

Annual Trend FY 2012 FY 2013 FY 2014 FY 2015 FY 2016 FY 2021 FY 2022 FY 2023 FY 2024 FY 2025 TTM
Total Revenue $54k
$15 -99.97%
$0 -100.00%
$0 $0 $209.7m
$222.0m +5.85%
$142.2m -35.94%
$574.1m +303.72%
$574.1m 0.00%
Cost of Goods and Services Sold $38k
$2 -99.99%
($22.0m)
$30.5m +238.84%
$4.0m -86.96%
($48.9m) -1328.36%
$48.9m +200.00%
Cost Of Revenue $23k $22.0m
$30.5m +38.84%
$29.1m -4.77%
$48.9m +68.26%
$48.9m 0.00%
Total cost of sales ($22.0m)
($30.5m) -38.84%
($29.1m) +4.77%
($48.9m) -68.26%
Net Interest Income ($43.1m)
($63.6m) -47.82%
($26.6m) +58.18%
$28.1m +205.41%
$28.1m 0.00%
Gross Profit $16k
$13 -99.92%
$187.7m
$191.4m +1.99%
$130.4m -31.90%
$525.2m +302.86%
$525.2m 0.00%
Research and development $743.1m $707.0m $129.8m $1.1b $1.1b
Selling, General and Administrative Expense $10k $5 $8k $29k $170.6m $181.1m $187.1m $246.3m $599.9m
Operating expenses:
Other Operating Expenses ($33.6m) ($19.4m) ($9.1m) ($14.5m)
Total Operating Expenses $114k $140k $163k $0 $348k $1.8b
EBIT ($834.4m) ($836.8m) ($330.8m) ($1.2b) ($1.2b)
Loss from operations ($98k) ($254k)
($833k) -227.40%
Other Non Operating Income Expenses ($3.1m) ($1.4m) ($4.4m) ($55.4m)
Interest Expense On Lease Liabilities $1.3m $205k $54.1m
Interest expense $2k ($11k) ($20k) ($28k) ($23k) $52.8m $96.1m $64.5m $54.1m $54.1m
Interest Income $9.7m $32.4m $37.8m $82.1m $82.1m
Net Non Operating Interest Income Expense ($43.1m) ($63.6m) ($26.6m) $28.1m $28.1m
Gain On Sale Of PPE $2.1m $4k ($50k) ($18k) ($18k)
Gain On Sale Of Security $7.0m $3.7m $5.9m ($11.3m) ($11.3m)
Other Income $59.3m $7.9m
Share Of Profit Loss Of Associates And Joint Ventures Accounted For Using Equity Method ($3) ($38k) ($38k) ($3)
Other income and gains $67.0m $59.3m $57.4m $103.5m
Other expenses ($17.7m) ($5.2m) ($9.1m) ($73.6m)
Non-Operating Income (Expense) $13k $0 ($155k)
Other Income Expense $5.7m $3.4m $1.1m ($66.4m) ($66.4m)
Net loss before income taxes ($155k) ($782k)
Income Before Tax ($144k) ($762k) ($1.2b)
Pre-Tax Income ($887.2m) ($932.9m) ($395.3m) ($1.2b) ($1.2b)
Deferred Tax Expense (Income) $0 $0 ($7.2m) $1.4m
Deferred Tax Expense (Income) Recognised In Profit Or Loss $0 $0 ($1.5m) ($3.9m)
Income Tax Expense Continuing Operations $163k $254k ($7.2m) $1.4m $6.9m
Income tax credit/(expense) $4.2m $7.2m ($10.4m) ($6.9m)
Income Tax Expense $0 $0 $6.9m
Net Income From Continuing And Discontinued Operation ($155k) ($782k) ($283k) ($1.5m) ($882.9m) ($925.6m) ($405.4m) ($1.2b) ($1.2b)
Net Income Continuous Operations ($155k) ($782k) ($283k) ($1.5m) ($882.9m) ($925.7m) ($405.7m) ($1.2b) ($1.2b)
Otherunder Preferred Stock Dividend $0 $0 $0
Basic Earnings (Loss) Per Share $-0.00 $-0.00 ($0.01) $-0.00 ($0.01) ($12.28) ($3.35) ($3.28) ($0.18) ($3.49) ($13.96)
Diluted Earnings (Loss) Per Share $-0.00 $-0.00 ($0.01) $-0.00 ($0.01) ($12.28) ($3.35) ($3.28) ($0.18) ($3.49) ($13.96)
Weighted Average Shares Outstanding, Diluted 145.5m 129.6m 31.5m 57.2m 127.8m $63.7m $65.9m $70.6m $75.5m
Basic Average Shares $145.5m $129.6m $31.5m $57.2m $127.8m $63.7m $65.9m $70.6m $75.5m $89.0m
Diluted Average Shares $145.5m $129.6m $31.5m $57.2m $127.8m $63.7m $65.9m $70.6m $75.5m $89.0m
Additional Financial Items
Depreciation Right of Use Assets $1.6m $1.5m $47.0m
Profit Loss Attributable To Noncontrolling Interests ($75k) ($34k)
Profit Loss Attributable To Owners Of Parent ($925.6m) ($55.5m)
Profit Loss Before Tax ($932.9m) ($54.1m)
Share of profit/(loss) of a joint venture ($278k) $1.1m ($281k) $314k
LOSS BEFORE TAX ($887.2m) ($932.9m) ($395.3m) ($1.2b)
LOSS FOR THE YEAR ($155k) ($782k) ($283k) ($1.5m) ($882.9m) ($925.7m) ($405.7m) ($1.2b)
Ordinary equity holders of the Company ($155k) ($782k) ($283k) ($1.5m) ($882.9m) ($925.6m) ($405.4m) ($1.2b)
Non-controlling interests ($75k) ($247k) ($218k)
Professional Fees $44k $129k $45k $37k
Extraordinary Items ($100k) ($140k)
Profit or Loss ($100k) ($169k) ($184k) ($283k)
Consulting fees $0 $269k
Consulting fees paid with stock $0 $118k
Loss due to revaluation of investment $0 ($9k)
Loss due to impairment of mineral rights $0 ($4k)
Loss on conversion of debt $0 ($506k)
Foreign exchange (loss) ($2k) ($6k)
Comprehensive (loss) ($285k) ($1.5m)
Stock-Based Compensation (Equity) $32k $7k
Income from Continuing Operations ($163k) ($254k)
Diluted EPS ($12.28) ($13.40) ($13.12) ($5.36) ($13.96)
Diluted NI Availto Com Stockholders ($155k) ($782k) ($283k) ($1.5m) ($882.9m) ($925.6m) ($405.4m) ($1.2b) ($1.2b)
Earnings From Equity Interest ($278k) $1.1m ($281k) $314k $314k
Minority Interests $0 $75k $247k $218k $218k
Normalized EBITDA ($780.5m) ($747.4m) ($243.4m) ($1.1b) ($1.1b)
Normalized Income ($891.9m) ($929.4m) ($409.8m) ($1.2b) ($1.2b)
Other Gand A $10k $5 $8k $29k $170.6m $181.1m $187.1m $246.3m
Other Special Charges $34k ($2.1m) ($4k)
Reconciled Depreciation $62.9m $93.2m $93.2m $86.5m $47.0m
Selling General And Administration $328.0m $376.5m $383.1m $599.9m
Special Income Charges $2.1m $4k ($50k) ($18k) ($18k)
Tax Effect Of Unusual Items $45k $29k $1.5m ($2.8m) ($2.8m)
Tax Provision ($4.2m) ($7.2m) $10.4m $6.9m $6.9m
Tax Rate For Calcs $0 $0 $0 $0 $0
Administrative Expense $181.1m $25.6m
Donations And Subsidies Expense $4.0m $866k
Expense Relating To Leases Of Low-Value Assets For Which Recognition Exemption Has Been Used $181k $33k
Expense Relating To Variable Lease Payments Not Included In Measurement Of Lease Liabilities $181k $33k
Finance Costs ($52.8m) $96.1m $8.8m ($54.1m)
Postemployment Benefit Expense Defined Contribution Plans $30.7m $4.7m
Selling Expense $195.4m $26.9m
Selling and distribution expenses ($157.4m) ($195.4m) ($196.0m) ($353.6m)
Other Operating Expense $0 $2k $195k $18k
Occupancy and Rent Expense $0 $548
Stock-Based Compensation Expense $16k $631k $7k $0
Operating Expense $1.0b $1.1b $1.3b $1.7b $1.7b
Total Unusual Items $9.0m $3.7m $5.8m ($11.3m) ($11.3m)
Total Expenses $1.1b $1.1b $1.4b $1.8b $1.8b

Values abbreviated: b = billions, m = millions, k = thousands. Per share data in USD.